Filing Details
- Accession Number:
- 0001209191-20-037339
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-17 17:14:20
- Reporting Period:
- 2020-06-15
- Accepted Time:
- 2020-06-17 17:14:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1501756 | Adverum Biotechnologies Inc. | ADVM | Biological Products, (No Disgnostic Substances) (2836) | 205258327 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1614875 | Mehdi Gasmi | C/O Adverum Biotechnologies, Inc. 800 Saginaw Drive Redwood City CA 94063 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-06-15 | 10,000 | $4.80 | 284,442 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-06-15 | 5,000 | $21.01 | 279,442 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-06-15 | 1,416 | $21.93 | 278,026 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-06-15 | 3,425 | $23.00 | 274,601 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-06-15 | 159 | $23.59 | 274,442 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-06-15 | 10,000 | $0.00 | 10,000 | $4.80 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
118,000 | 2026-02-11 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 plan.
- Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.50 to $21.49. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Price reported is a weighted-average sales price. The shares were sold at prices ranging from $21.51 to $22.42. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Price reported is a weighted-average sales price. The shares were sold at prices ranging from $22.55 to $23.39. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Price reported is a weighted-average sales price. The shares were sold at prices ranging from $23.57 to $23.63. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Fully vested and exercisable.